What does Boppli® cost?

A price-estimate guide for neonatal continuous blood pressure monitoring with transparent caveats on available data

Boppli received FDA 510(k) Class II clearance in September 2023 as a noninvasive blood pressure measurement system . Despite its regulatory status and commercial availability since late 2023, Boppli pricing remains opaque—neither PyrAmes Health nor its distribution partner Sentec disclose list prices, contract pricing, or per-unit band costs on publicly available channels. This article reflects what can be verified as of May 2026; pricing data will be updated as quotes accumulate in the MedSource database.

What the typical range might be

No publicly verifiable pricing exists in FDA 510(k) summaries, manufacturer spec sheets, GSA schedules, or competitive benchmark literature. Early adopter NICUs negotiated pricing under confidentiality agreements. The Boppli system requires two components— a single-use, battery-powered band and a reusable Bedside Device —which suggests a two-part cost structure (capital equipment + consumables), but per-unit band cost and Bedside Device pricing are not public. Until MedSource collects direct quotes, procurement officers should request samples from PyrAmes sales or Sentec regional reps and expect variability based on volume commitments, service tier, and contract length.

What pushes price up — features, certifications, support tier

Regulatory and clinical validation burden. The device was backed by 3,400 hours of clinical validation and demonstrated accuracy within FDA guidelines in a rigorous, pivotal clinical study at multiple neonatal intensive care units in the U.S. and Canada . This level of clinical evidence is expensive to generate and may be reflected in initial pricing.

No calibration required. Boppli does not require calibration , which reduces ongoing maintenance cost compared to arterial line monitoring, but this feature may carry a premium for the underlying sensor algorithms and machine-learning architecture.

Wireless integration and connectivity. The Bedside Device enables live monitoring of blood pressure and pulse rate, as well as review of data previously recorded . Software licensing, Bluetooth connectivity, and data storage/display capabilities on the reusable bedside monitor likely factor into equipment cost.

Early market entry. Boppli is the only commercially-available, continuous and non-invasive BP monitoring solution for infants , creating no direct price competition. Monopoly pricing—higher than eventual market entry would suggest—is typical for first-mover medical devices, especially in pediatric/neonatal niches.

What pushes price down — refurbished, older generation, lease, GPO contracts

Lease vs. purchase. No evidence of lease programs has been published. If available, leasing a Bedside Device (capital equipment) while purchasing bands as consumables may distribute cost, but terms are not public.

Group Purchasing Organization (GPO) discounts. Large hospital systems and pediatric networks may negotiate GPO pricing through Sentec, but no published benchmark exists. Inquire with your healthcare system's GPO (e.g., Vizient, Medline, HealthTrust) on Boppli eligibility.

Volume commitments. Standard practice for single-use device manufacturers suggests per-band pricing declines with annual volume commitments (500, 1,000, 5,000+ units/year), but no tiered pricing has been disclosed.

Second-generation hardware. No older-generation Boppli devices or refurbished systems are known to be in circulation yet; the product launched commercially in fall 2023.

Hidden costs — install, training, calibration, consumables, service contracts

No installation or calibration. Boppli avoids calibration costs unlike arterial line setup (provider time, materials). Clinical training is minimal: nurses reported the device was easy to use (5.3/6 on a usability scale) , suggesting lower training overhead than complex monitoring systems.

Consumable cost structure is critical. The Boppli Band is single-use , meaning each patient or monitoring episode requires a new band. In a 300-bed NICU with ~100 monitored infants at any time, band consumption could easily reach 2,000–5,000 units annually if deployed across typical 72-hour NICU stays. Per-band cost is the largest driver of total cost of ownership but is not published. Request this explicitly in RFPs.

Battery replacement for single-use bands. The band is battery-powered and designed for ~72-hour continuous use. After disposal, no battery recycling or recharging occurs (per design). Factor in medical waste disposal costs for single-use devices.

Service agreements. No public SLAs or preventive maintenance contracts for the Bedside Device have been disclosed. Warranty coverage (1–2 years typical) and extended service plans should be negotiated. Sentec's reputation for support should be verified with existing customers.

Integration with existing EMR/bedside monitors. Boppli data integration into hospital EMR systems or wireless bedside monitoring networks may require IT configuration time and potentially vendor licensing fees. Confirm interoperability with your current infrastructure (e.g., Philips, GE, Medtronic bedside monitors).

How to negotiate — concrete tactics

1. Request per-band cost and per-year volume pricing tiers. PyrAmes and Sentec must provide this; it is non-negotiable for budget planning. Ask for separate pricing: Bedside Device (one-time capital), per-band, and support/warranty.

2. Benchmark against arterial line cost displacement. Compare total cost of ownership (device + consumables + training + complications avoided) against current IAL monitoring costs. A typical arterial line insertion costs $2,000–5,000 when accounting for provider time, materials, and complications. If a Boppli band + monitoring costs <$500/patient, it may be cost-neutral or positive on a per-case basis.

3. Pilot before full deployment. Negotiate a limited pilot (10–20 beds, 50–100 patients) with defined pricing and performance SLAs. This allows clinical validation and accurate cost modeling before enterprise commitment.

4. Inquire about reference accounts and published case studies. Ask Sentec for 3–5 NICU customers willing to share adoption costs, band utilization rates, and clinical outcomes. Published health economics data is sparse, and peer experience is invaluable.

5. Clarify Bedside Device multi-patient use. Can one Bedside Device support multiple bands/patients sequentially, or does each bed require a dedicated monitor? This significantly affects capital cost per NICU bed.

6. Negotiate service, warranty, and training terms. Standard device warranties are 1–2 years; negotiate extended coverage if planning multi-year adoption. Include onsite or remote training for nursing and respiratory staff.

7. Ask about supply chain and lead time. Early-stage manufacturers sometimes face manufacturing constraints. Confirm band availability, reorder lead times, and supply guarantees before committing.

When the price feels off — red flags

• No published per-band cost. If PyrAmes or Sentec will not disclose consumable pricing after the first conversation, this suggests either underdeveloped commercial operations or intentional pricing opacity.
• Bundled pricing without component breakdown. Refuse all-in pricing that does not separate capital, consumables, and support; you cannot benchmark or forecast costs properly.
• Lack of published clinical outcomes or health economics data. By May 2026, at least one peer-reviewed cost-effectiveness analysis should exist. If absent, the economic case is not yet established.
• Unavailable reference accounts. A new device should have 10+ published customers willing to discuss outcomes. Reluctance suggests poor early adoption or dissatisfaction.
• Exclusive distribution through Sentec only. While Sentec is the commercial partner, confirm there is no price-locking risk or sole-source dependency that prevents future competition.
• No mention of band failure rates or rework. Single-use devices sometimes fail or disconnect prematurely. Request published defect rates and clarify whether failed bands are replaced at no cost during the warranty period.

Sources

• FDA 510(k) Clearance Summary, PyrAmes Boppli Infant Blood Pressure Monitor, September 29, 2023. (https://www.accessdata.fda.gov/cdrh_docs/pdf22/K223873.pdf)
• Hunter, R. B., et al. "Accuracy and Safety of a Continuous Noninvasive Blood Pressure Monitor in Neonates." Neonatology, vol. 122, no. 5, May 2025, pp. 595–605. doi: 10.1159/000546187.
• PyrAmes Health / Sentec North America Partnership Announcement, September 13, 2022. (https://pyrameshealth.com/sentec-and-pyrames-form-partnership-to-bring-noninvasive-care-to-critically-ill-infants/)
• PyrAmes Health Boppli Platform Specification & Clinical Overview. (https://pyrameshealth.com/our-platforms/boppli-platform/)

---

Note: This article reflects publicly available data as of May 5, 2026. MedSource does not yet hold aggregate pricing or contract data for Boppli. Pricing will be updated quarterly as procurement data accumulates from hospital buyers. Procurement officers should contact Sentec North America or PyrAmes directly for current list pricing and volume discounts.